SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
Key result
SGLT-2 inhibitors offer promising therapeutic prospects for heart failure management by addressing current unmet clinical needs.
Why the study?
Heart failure represents an increasing public health and healthcare burden with unmet management needs, prompting a review of the potential therapeutic role of SGLT-2 inhibitors.
Design
Narrative review
Authors
Discussion
Loading...
Member takes
Implication
Does not support practice change in heart failure; leaves open efficacy and safety questions for randomized trials.
Key Points
- The aim is to explore the management challenges of heart failure and the therapeutic prospects of SGLT-2 inhibitors.
- Reviewed current literature on heart failure management and trends in patient populations.
- Analyzed the role of SGLT-2 inhibitors in addressing these management challenges.
- Heart failure is projected to increase in prevalence, especially among older populations.
- SGLT-2 inhibitors show promise in improving management strategies for heart failure patients, particularly those with a preserved ejection fraction.
Cite This Study
Lam et al. (2019) studied this question. SGLT-2 inhibitors offer promising therapeutic prospects for heart failure management by addressing current unmet clinical needs.